Health technology assessment : HTA
-
Health Technol Assess · Oct 2014
ReviewKRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.
Bowel cancer is the third most common cancer in the UK. Most bowel cancers are initially treated with surgery, but around 17% spread to the liver. When this happens, sometimes the liver tumour can be treated surgically, or chemotherapy may be used to shrink the tumour to make surgery possible. Kirsten rat sarcoma viral oncogene (KRAS) mutations make some tumours less responsive to treatment with biological therapies such as cetuximab. There are a variety of tests available to detect these mutations. These vary in the specific mutations that they detect, the amount of mutation they detect, the amount of tumour cells needed, the time to give a result, the error rate and cost. ⋯ The National Institute for Health Research Health Technology Assessment programme.
-
Health Technol Assess · Oct 2014
ReviewThe clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.
Optimal therapy for children with chronic hepatitis C is unclear. Two treatment regimens are currently licensed in children. ⋯ The National Institute for Health Research Health Technology Assessment programme.